highly significantP < .0001
The pooled analysis demonstrated a highly significant overall RR of 4.51 (95% CI, 2.95-6.90, P < .0001) for adverse outcomes in the high-risk TGF-β1 group compared with the low-risk group.
The pooled analysis demonstrated a highly significant overall RR of 4.51 (95% CI, 2.95-6.90, P < .0001) for adverse outcomes in the high-risk TGF-β1 group compared with the low-risk group.